IL144764A0 - Eplerenone crystalline form exhibiting enhanced dissolution rate - Google Patents

Eplerenone crystalline form exhibiting enhanced dissolution rate

Info

Publication number
IL144764A0
IL144764A0 IL14476400A IL14476400A IL144764A0 IL 144764 A0 IL144764 A0 IL 144764A0 IL 14476400 A IL14476400 A IL 14476400A IL 14476400 A IL14476400 A IL 14476400A IL 144764 A0 IL144764 A0 IL 144764A0
Authority
IL
Israel
Prior art keywords
crystalline form
dissolution rate
exhibiting enhanced
enhanced dissolution
form exhibiting
Prior art date
Application number
IL14476400A
Other languages
English (en)
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of IL144764A0 publication Critical patent/IL144764A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL14476400A 1999-12-08 2000-12-04 Eplerenone crystalline form exhibiting enhanced dissolution rate IL144764A0 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US16969099P 1999-12-08 1999-12-08
US16963999P 1999-12-08 1999-12-08
US16955699P 1999-12-08 1999-12-08
US16960899P 1999-12-08 1999-12-08
US16980799P 1999-12-08 1999-12-08
US16968299P 1999-12-08 1999-12-08
PCT/US2000/032416 WO2001042272A2 (en) 1999-12-08 2000-12-04 Eplerenone crystalline form exhibiting enhanced dissolution rate

Publications (1)

Publication Number Publication Date
IL144764A0 true IL144764A0 (en) 2002-06-30

Family

ID=27558585

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14476400A IL144764A0 (en) 1999-12-08 2000-12-04 Eplerenone crystalline form exhibiting enhanced dissolution rate
IL144764A IL144764A (en) 1999-12-08 2001-08-06 A crystalline form of applernon that reveals an increased rate of decay
IL176511A IL176511A (en) 1999-12-08 2006-06-22 A crystalline form of applernon that reveals an increased rate of decay

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL144764A IL144764A (en) 1999-12-08 2001-08-06 A crystalline form of applernon that reveals an increased rate of decay
IL176511A IL176511A (en) 1999-12-08 2006-06-22 A crystalline form of applernon that reveals an increased rate of decay

Country Status (18)

Country Link
EP (1) EP1177204A2 (zh)
JP (1) JP2003516414A (zh)
KR (1) KR100607923B1 (zh)
CN (2) CN1557833A (zh)
AU (1) AU784946B2 (zh)
BR (1) BR0008057A (zh)
CA (1) CA2362669A1 (zh)
CO (1) CO5280211A1 (zh)
EA (1) EA007934B1 (zh)
HK (1) HK1050536A1 (zh)
HU (1) HUP0203032A3 (zh)
IL (3) IL144764A0 (zh)
MX (1) MXPA01008056A (zh)
MY (1) MY131878A (zh)
NO (1) NO20013856L (zh)
NZ (2) NZ530028A (zh)
PE (1) PE20010917A1 (zh)
WO (1) WO2001042272A2 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003225871A1 (en) * 2002-03-20 2003-10-08 Pharmacia Corporation Storage stable eplerenone formulation
US7235655B2 (en) 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
CA2582496A1 (en) 2007-03-20 2008-09-20 Apotex Pharmachem Inc. Improved process for the preparation and purification of eplerenone
US8957052B2 (en) 2010-05-10 2015-02-17 Universite Paris Descartes Methods and compositions for the treatment of fluid accumulation in and/or under the retina
US9241944B2 (en) 2010-06-16 2016-01-26 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and compositions for stimulating reepithelialisation during wound healing
JP6835836B2 (ja) 2015-10-13 2021-02-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 脈絡膜血管新生の処置のための方法及び医薬組成物
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
CN108059648A (zh) * 2017-12-30 2018-05-22 合肥久诺医药科技有限公司 一种依普利酮溶剂合物及其制备方法
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea
WO2023204729A1 (ru) * 2022-04-19 2023-10-26 Общество с ограниченной ответственностью "Гелеспон" Фармацевтические композиции на основе новой субстанции 4-[2-(1н-имидазол-4-ил)-этилкарбамоил]-бутановой кислоты и способ получения субстанции

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559332A (en) * 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
ES2293944T3 (es) * 1996-12-11 2008-04-01 G.D. Searle Llc. Procedimiento de epoxidacion.
PT1165136E (pt) * 1999-03-05 2004-02-27 Searle Llc Terapia de combinacao de inibidores da enzima de conversao da antagonista da aldosterona epoxi-esteroidal para tratamento de doenca cardiovascular

Also Published As

Publication number Publication date
IL176511A (en) 2007-08-19
AU784946B2 (en) 2006-08-03
WO2001042272A2 (en) 2001-06-14
NO20013856L (no) 2001-10-08
CA2362669A1 (en) 2001-06-14
EA200100871A1 (ru) 2002-04-25
HUP0203032A2 (hu) 2002-12-28
PE20010917A1 (es) 2001-09-10
HUP0203032A3 (en) 2003-04-28
WO2001042272A9 (en) 2002-12-12
JP2003516414A (ja) 2003-05-13
KR20010112261A (ko) 2001-12-20
NO20013856D0 (no) 2001-08-08
AU2049201A (en) 2001-06-18
CN1377365A (zh) 2002-10-30
HK1050536A1 (en) 2003-06-27
MXPA01008056A (es) 2003-07-21
CO5280211A1 (es) 2003-05-30
CN1152886C (zh) 2004-06-09
NZ513961A (en) 2004-02-27
MY131878A (en) 2007-09-28
IL144764A (en) 2007-08-19
NZ530028A (en) 2005-08-26
KR100607923B1 (ko) 2006-08-04
CN1557833A (zh) 2004-12-29
EA007934B1 (ru) 2007-02-27
BR0008057A (pt) 2002-04-23
WO2001042272A3 (en) 2001-11-29
EP1177204A2 (en) 2002-02-06

Similar Documents

Publication Publication Date Title
HK1039897A1 (zh) 選擇性醛甾酮受體拮抗劑「eplerenone」毫微粒子合成物
EP1196147A4 (en) BUILDING COMPOSITIONS
HK1044476A1 (en) Medicinal compositions
AU142262S (en) Towel
EP1166786A4 (en) MEDICAL COMPOSITIONS
HK1044768A1 (zh) 晶狀1-甲基碳青霉烯化合物
IL144764A0 (en) Eplerenone crystalline form exhibiting enhanced dissolution rate
GB0016698D0 (en) Tie
HK1057220A1 (en) Eplerenone crystalline form
AU5092001A (en) Crystalline pharmaceutical
AP2001002234A0 (en) Crystalline therapeutic agent
ZA200107145B (en) Eplerenone crystalline form exhibiting enhanced dissolution rate.
CA86215S (en) Towel
HUP0003380A2 (en) Reversible plough
SI1305314T1 (en) Crystalline therapeutic agent
CA89270S (en) Tie
CA86216S (en) Towel
CA86214S (en) Towel
TW414329U (en) Clock structure for displaying multiple times
GB9925372D0 (en) Tie
GB0001176D0 (en) Tie
HU0002045D0 (en) Unipolar crystal
GB9906607D0 (en) Oral composition
GB9910326D0 (en) Ploughs
TW417500U (en) Improved sandbag structure

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed